Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

about

P2860

Q36247037-E5A66D62-A283-4636-89E9-478E5364E379 Q38810330-29B42C4E-C0D9-4A00-B43F-81138C9DF425 Q39453613-BE4AC84A-233E-4387-A536-31620E12DE65 Q55105693-02FE9DF0-E203-4270-8821-9B49D49371A6

P2860

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

Item

http://www.wikidata.org/entity/Q38564601

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

@en

type

Item

label

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

@en

prefLabel

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

@en

P1476

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

@en

P2093

Dong-Churl Suh

http://www.w3.org/2001/XMLSchema#string

Scott K Griggs

http://www.w3.org/2001/XMLSchema#string

Taehwan Park

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in published cost effectiveness studies: systematic review.

Orphan drugs and the NHS: should we value rarity?

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.

Orphan drug development: an economically viable strategy for biopharma R&D.

Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial.

The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal.

Drugs for exceptionally rare diseases: do they deserve special status for funding?

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada.

A comparative study of European rare disease and orphan drug markets.

A systematic review of the cost effectiveness of herpes zoster vaccination.

P2888

s40259-015-0135-4

P304

259-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40259-015-0135-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26263903

http://www.w3.org/2001/XMLSchema#string

P921

rare disease

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

about

P2860

P2860

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921